Applications

1813 – Detection of measurable residual disease in patients with acute myeloid leukaemia

Find out about the service or technology in application 1813 and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input, and the outcome of the application when the MSAC process is complete.

  • Status Pre-assessment
  • Type New application
  • Pre-PASC consultation Open
  • Pre-MSAC consultation Not yet started
  • Outcome Pending

Application details

Applicant

The Royal College of Pathologists of Australasia

Reason for application

New Medicare Benefits Schedule item.

Service or technology in this application

Measurable residual disease (MRD) testing uses very sensitive laboratory methods to look for tiny amounts of leukaemia cells that may persist after treatment, particularly levels too low to see under a microscope. The main test methods used are flow cytometry and molecular methods including quantitative polymerase chain reaction testing (qPCR) and next-generation sequencing (NGS). MRD test results can be used by doctors to estimate the chance of leukaemia relapse and decide if more or less intensive treatment is needed. 

Medical condition this application addresses

Acute myeloid leukaemia (AML) is an aggressive blood cancer that starts in the bone marrow, the site of normal blood cell production. In AML, immature white blood cells known as “blasts” proliferate uncontrollably, displacing healthy blood cells. Patients typically present with symptoms such as fatigue, recurrent infections, and bleeding. Despite initial treatment, patients with AML frequently relapse, and this type of leukaemia is associated with poor long-term survival outcomes.

Consultation survey and deadlines

The following consultation deadlines apply:

  • Pre-PASC consultation deadline: Friday March 13 2026 11:59pm AEDT
  • Pre-MSAC consultation deadline: To be confirmed

For other ways to provide input, see how to have your say.

We welcome input from everyone. We are especially keen to hear from those with lived experience of the health condition, service or technology the applications are addressing.

Find out more about consultation.

Meetings to consider this application

This application will be considered at the following meetings:

  • PASC meeting: 16 to 17 April 2026
  • ESC meeting: To be confirmed
  • MSAC meeting: To be confirmed

Find out more about our meetings.

Outcome details

The outcome of this application is pending.

More information

Find out more about: